NCT03751176 - Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 8, 2018

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2022

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG

Panitumumab

Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy

DRUG

Irinotecan

Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1

DRUG

Folinic acid

Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1

DRUG

5-FU

5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2

Trial Locations (18)

17007

ICO Girona Dr. Josep Trueta, Girona

28041

Hospital 12 de Octubre, Madrid

28046

Hospital Universtiario la Paz, Madrid

28050

CIOCC Sanchinarro, Madrid

28922

Hospital Universitario Fundación Alcorcón, Alcorcón

31008

Complejo Hospitalario de Navarra, Navarro

43204

H. Universitari Sant Joan de Reus, Reus

46009

Fundación Instituto Valenciano de Oncología, Valencia

46017

Hospital Universitario Dr. Peset, Valencia

46026

Hospital Universitario y Politécnico La Fe, Valencia

46600

Hospital de La Ribera de Alzira, Alzira

08402

Hospital de Granollers, Granollers

08221

Hospital Mutua de Terrassa, Terrassa

03203

Hospital General Universitario de Elche, Alicante

08035

Hospital Universitario Vall d'Hebron, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

08041

Hospital de la Santa Creu I Sant Pau, Barcelona

08208

Corporació Sanitaria Parc Taulí, Sabadell